Cemiplimab

Category: Cancer



Cemiplimab Overview

Cemiplimab (REGN-2810) is a monoclonal antibody under development as a drug for the treatment of squamous cell skin cancer,[1] myeloma,[2] and lung cancer.[3] In Sept 2018 it was approved by the US FDA for treating "patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation". [4] cemiplimab-rwlc will be marketed as Libtayo.[4...

Read more Cemiplimab Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Cemiplimab

Recent Cemiplimab Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Cemiplimab
  • Injection: 350mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Cemiplimab or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 20 February 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA